**7.2 Programmatic Management of Drug Resistant TB services (PMDT)**

PMDT services were first offered in 2007, and by 2013, the programme had expanded to encompass the entire country. During 2011–2012, a systematic approach to scaling up all of these facilities was implemented, with coordinated efforts from numerous stakeholders resulting in national coverage by 2013. Line Probe Assay (LPA) was first presented in 2009, followed by CBNAAT in 2012, and both technologies have now been scaled up to 64 LPA labs, 1180 CBNAAT sites, and 350 TrueNAT sites by the end of 2019. By implementing Guidelines for PMDT in India 2017, DRTB treatment services are delegated to district DRTB centres with the goal of bringing drug resistant TB treatment closer to TB patients' homes. By the end of 2019, 711 DR TB centres, including 154 Nodal DR TB centres, will be operational, allowing for decentralised DR-TB treatment. This decentralisation will enable districts to use the "test and treat approach" to shorten diagnostic and treatment delays, reduce travel costs, and speed early MDR/RR-TB patient care within their district [16].
